Novartis CEO ‘very confident’ on sales target, doesn’t fear patent cliff
ZURICH (Reuters) - Novartis (SIX:) expects to increase its annual sales by least 5% per year in the coming years, ...
Monday, April 28, 2025
Tag: Novartis
Novartis oral Fabhalta ® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial By Investing.com
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate ...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.